Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/01/2026 ,inter alia, to consider and approve the unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has informed BSE that its Board of Directors will meet on Thursday, January 15, 2026, at the registered office. The key item on the agenda is to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26). The company has also notified that the trading window for dealing in its securities is closed from January 1, 2026, until 48 hours after the results are made public on January 15, 2026, for directors, KMPs, promoters, and designated persons. This is a routine regulatory intimation under SEBI LODR Regulation 29.
This is a standard pre-results announcement with no financial data disclosed yet. Shareholders should watch for the actual Q3 FY26 results on January 15, 2026, for any meaningful performance insights. The closed trading window means insiders cannot trade until after the results are published.